This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Company News for April 26, 2017
by Zacks Equity Research
Companies in the News are: RAD,GLW,LLY,NFLX
Lilly (LLY) Tops Q1 Earnings, Misses Sales, Shares Down
by Zacks Equity Research
Eli Lilly and Company (LLY) reported first-quarter 2017 adjusted earnings per share of 98 cents, which beat the Zacks Consensus Estimate of 96 cents by 2.1%.
Key Factors to Look Out for in Celgene's (CELG) Q1 Results
by Arpita Dutt
Apart from the usual earnings and revenue numbers, investors will be focused on the performance of Celgene's (CELG) key products and its pipeline progress.
Eli Lilly (LLY) Tops Earnings in Q1; Sales Miss Slightly
by Zacks Equity Research
Eli Lilly (LLY) Tops Earnings in Q1; Sales Miss Slightly
What's in Store for Vertex (VRTX) this Earnings Season?
by Zacks Equity Research
Vertex Pharmaceuticals, Inc. (VRTX) is scheduled to report first-quarter 2017 results on Apr 27, after the market closes.
3 Key Factors to Look Out for in Biogen's Q1 Results
by Arpita Dutt
With Biogen (BIIB) set to report Q1 results tomorrow, here is a look at 3 key factors investors will be focused on apart from earnings and revenue.
Why Eli Lilly (LLY) Might Surprise This Earnings Season
by Zacks Equity Research
Eli Lilly (LLY) is seeing encouraging earnings estimate revision activity as of late and carries a favorable rank, positioning the company for a likely beat this season.
S&P Global (SPGI) to Post Q1 Earnings: A Beat in the Cards?
by Zacks Equity Research
S&P Global, Inc. (SPGI) is slated to report first-quarter 2017 results on Apr 25, before the markets open.
TransUnion (TRU) Q1 Earnings: What's in Store this Time?
by Zacks Equity Research
TransUnion (TRU) is scheduled to release first-quarter 2017 results before the market opens on Apr 25.
Eli Lilly (LLY) Up 8.1% Since Earnings Report: Can It Continue?
by Zacks Equity Research
Eli Lilly (LLY) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Drug Stocks Q1 Earnings Releases on Apr 25: LLY, BIIB, NVS
by Zacks Equity Research
As the Q1 earnings season gets in full swing this week, we believe this quarter is on track to see the highest growth in almost three years.
CytRx Gets Clarity from FDA for Aldoxorubicin NDA, Shares Up
by Zacks Equity Research
CytRx Corporation (CYTR) announced that the it has reached an agreement with the regarding the path to filing for its new drug application (NDA) for its lead candidate aldoxorubicin being developed for the treatment of soft tissue sarcomas (STS).
Eli Lilly (LLY) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
Eli Lilly and Company (LLY) will report first-quarter 2017 results on Apr 25, before the market opens.
Company News for April 18, 2017
by Zacks Equity Research
Companies in the News are: MGI,LLY,ASH,ALR,ABT
5 Major Drug Stocks Likely to Beat Q1 Earnings Estimates
by Zacks Equity Research
2017 is expected to be a strong year for drug stocks.
Eli Lilly's Rheumatoid Arthritis Drug Gets CRL in the U.S.
by Zacks Equity Research
Eli Lilly and Company (LLY) and its partner Incyte Corporation (INCY) recently announced that they have received a Complete Response Letter (CRL) from the FDA regarding the new drug application (NDA) for baricitinib.
Zoetis (ZTS) Inks Agreement to Acquire Nexvet Biopharma
by Zacks Equity Research
Zoetis Inc. (ZTS) announced an agreement to buy Nexvet Biopharma plc (NVET) for an aggregate equity valuation of approximately $85 million
What's in the Cards for IDEX (IEX) this Earnings Season?
by Zacks Equity Research
IDEX Corporation (IEX) is scheduled to report first-quarter 2017 results after the closing bell on Apr 19.
Profit from These 5 Sturdy Stocks as Fear Grips Markets
by Tirthankar Chakraborty
Wall Street's fear gauge is breaking out higher as geopolitical risks heat up after the U.S. opted for 'Mother of All Bombs'.
J&J (JNJ) to Kick Off Pharma Q1 Earnings: Will it Beat?
by Zacks Equity Research
We expect Johnson & Johnson (JNJ), a healthcare bellwether, to beat expectations when it reports first-quarter 2017 results on Apr 18, before the opening bell.
What's in the Cards for Omnicom (OMC) this Earnings Season?
by Zacks Equity Research
Omnicom Group Inc. (OMC) is scheduled to report first-quarter 2017 results before the opening bell on Apr 18.
ANTH's (ANTH) Blisibimod Completes Dosing in Phase III Study
by Zacks Equity Research
Anthera Pharmaceuticals, Inc. (ANTH) recently announced the completion of dosing in a phase II study, BRIGHT-SC. The study evaluated key pipeline candidate blisibimod for treatment of patients with IgA nephropathy (IgAN).
Merck's Bid to Add Cardiovascular Data on Januvia Label Fails
by Zacks Equity Research
Merck announced that the FDA has denied approval to include cardiovascular outcomes data on the labels of its diabetes drug, Januvia (sitagliptin) and other medicines containing Januvia.
Infinity Pharmaceuticals Focuses on Lead Candidate IPI-549
by Zacks Equity Research
We issued an updated report on Infinity Pharmaceuticals, Inc. (INFI) on Apr 7.
Novartis (NVS) In-Licenses Ophthalmic Drug from Lubris LLC
by Zacks Equity Research
Novartis AG (NVS) recently announced that it has exercised an option to in-license ECF843 for ophthalmic indications worldwide from Lubris LLC.